|
|
|
| Research progress of obesity cardiomyopathy |
| ZHAO Gaowa1,2 YU Qin1,2 |
1.Department of Cardiology, Affiliated Zhongshan Hospital of Dalian University, Liaoning Province, Dalian 116001, China;
2.Zhongshan Clinical College, Dalian University, Liaoning Province, Dalian 116622, China |
|
|
|
Abstract Obesity is a chronic metabolic disease caused by a variety of factors. It is now considered as an independent risk factor for cardiovascular disease. Long term severe obesity can lead to changes in the structure and function of the heart, and eventually result to heart failure. Obesity cardiomyopathy is a metabolic disease caused by obesity. At present, with the improvement of living standards, the number of obese people is increasing, and the incidence of obesity cardiomyopathy is increasing gradually. Therefore, correct understanding of obesity cardiomyopathy and early prevention, diagnosis and treatment can significantly reduce the prevalence of obesity cardiomyopathy. This article reviews the diagnosis, pathogenesis and treatment of obesity cardiomyopathy.
|
|
|
|
|
|
[1] Sorop O，Olver TD，Wouw JVD，et al. Themicrocirculation：A key player in obesity-associated cardiovascular disease [J]. Cardiovasc Res，2017，113（9）：1035-1045.
[2] Willius FA，Smith HL. Factors concerned in cardiac hypertrophy：A study made at necropsy of seventy-nine cases of rheumatic heart disease [J]. AHT，2010（2）：190-207.
[3] GBD 2015 Obesity Collaborators，Afshin A，Forouzanfar MH，et al. Health Effects of Overweight and Obesity in 195 Countries over 25 Years [J]. N Engl J Med，2017，377（1）：13-27.
[4] Horwich TB，Fonarow GG. Glucose，obesity，metabolic syndrone，and biabetes relevance to incidence of heart failure [J]. J Am Coll Cardiol，2010，55（4）：283-293.
[5] Kenchaiah S，Evans JC，Levy D，et al. Obesity and the risk of heart failure [J]. N Engl J Med，2002，347（5）：305-313.
[6] Wong C，Marwick TH. Obesity cardiomyopathy：pathogenesis and pathophysiology [J]. Nat Clin Pract Cardiovasc Med，2007，4（8）：436-443.
[7] Frisbee JC. Obesity，insulin resistance，and microvascular adaptation[J]. Microcirculation，2017，24（2）：e12346.
[8] Marsico F，Gargiulo P，Marra AM，et al. Glucose Metabolism Abnormalities in Heart Failure Patients：Insights and Prognostic Relevance [J]. Heart Fail Clin，2019，15 （3）：333-340.
[9] Velez M，Kohli S，Sabbah HN，et al. Animal models of insulin resistance and heart failure [J]. Heart Fail Rev，2014， 19（1）：1-13.
[10] Chistiakov DA，Orekhov AN，Bobryshev YV. The impact of FOXO-1 to cardiac pathology in diabetes mellitus and diabetes-related metabolic abnormalities [J]. Int J Cardiol，2017，245：236-244.
[11] Ouchi N，Ohashi K，Shibata R，et al. Protective Roles of Adipocytokines and Myokines in Cardiovascular Disease [J]. Circ J，2016，80（10）：2073-2080.
[12] Balasubramanian P，Hall D，Subramanian M. Sympathetic nervous system as a target for aging and obesity-related cardiovascular diseases [J]. Geroscience，2019，41（1）：13-24.
[13] van Hout GPJ，Bosch L. The Inflammasomes in Cardiovascular Disease [J]. Exp Suppl，2018，108：9-40.
[14] Bartekova M，Radosinska J，Jelemensky M，et al. Role of cytokines and inflammation in heart function during health and disease [J]. Heart Fail Rev，2018，23（5）：733-758.
[15] Zhai AB，Haddad H. The impact of obesity on heart failure [J]. Curr Opin Cardiol，2017，32（2）：196-202.
[16] Gao CL，Zhu C，Zhao YP，et al. Mitochondrial dysfunction is induced by high levels of glucose and free fatty acids in 3T3-L1 adipocytes [J]. Mol Cell Endocrinol，2010，320（1/2）：25-33.
[17] Wang D，Yan S，Yan J，et al. Effects of triphenyl phosphate exposure during fetal development on obesity and metabolic dysfunctions in adult mice：Impaired lipid metabolism and intestinal dysbiosis [J]. Environ Pollut，2019，246：630-638.
[18] Forrester SJ，Kikuchi DS，Hernandes MS，et al. Reactive oxygen species in metabolic and inflammatory signaling [J]. Circ Res，2018，122（6）：877-902.
[19] Tsujimoto T，Kajio H. Abdominal Obesity Is Associated With an Increased Risk of All-Cause Mortality in Patients With HFpEF [J]. J Am Coll Cardiol，2017，70（22）：2739-2749.
[20] Incalza MA，D′Oria R，Natalicchio A，et al. Oxidative stress and reactive oxygen species in endothelial dysfunction associated with cardiovascular and metabolic diseases [J]. Vascul Pharmacol，2018，100：1-19.
[21] Goossens GH. The Metabolic Phenotype in Obesity：Fat Mass，Body Fat Distribution，and Adipose Tissue Function [J]. Obes Facts，2017，10（3）：207-215.
[22] Atawia RT，Bunch KL，Toque HA，et al. Mechanisms of obesity-induced metabolic and vascular dysfunctions [J]. Front Biosci （Landmark Ed），2019， 24：890-934.
[23] Bauml MA，Underwood DA. Left ventricular hypertrophy：An overlooked cardiovascular risk factor [J]. Cleve Clin J Med，2010，77（6）：381-387.
[24] Alpert MA，Karthikeyan K，Abdullah O，et al. Obesity and Cardiac Remodeling in Adults：Mechanisms and Clinical Implications [J]. Prog Cardiovasc Dis，2018，61（2）：114-123.
[25] Pathak RK，Mahajan R，Lau DH，et al. The implications of obesity for cardiac arrhythmia mechanisms and management [J]. Can J Cardiol，2015，31（2）：203-210.
[26] Lavie CJ，Pandey A，Lau DH，et al. Obesity and Atrial Fibrillation Prevalence，Pathogenesis，and Prognosis：Effects of Weight Loss and Exercise [J]. J Am Coll Cardiol，2017，70（16）：2022-2035.
[27] Clark AL，Fonarow GC，Horwich TB. Obesity and the Obesity Paradox in Heart Failure [J]. Can J Cardiol，2013，56（4）：409-414.
[28] Marinou K，Hodson L，Vasan SK，et al. Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men [J]. Diabetes Care，2014，37：821-829.
[29] Kragelund C，Hassager C，Hildebrandt P，et al. Impact of obesity on long-term prognosis following acute myocardial infarction [J]. Int J Cardiol，2005，98（1）：123-131.
[30] Antonopoulos AS，Margaritis M，Verheule S，et al. Mutual Regulation of Epicardial Adipose Tissue and Myocardial Redox State by PPAR-gamma/Adiponectin Signalling [J]. Circ Res，2016，118（5）：842-855.
[31] Díez J. Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system：implications for therapy [J]. Eur J Heart Fail，2017，19（2）：167-176.
[32] Antonopoulos AS，Oikonomou EK，Antoniades C，et al. From the BMI paradox to the obesity paradox：the obesity-mortality association in coronary heart disease [J]. Obes Rev，2016，17（10）：989-1000.
[33] Keshava HB，Mowla A，Heinberg LJ，et al. Bariatric surgery may reduce the risk of Alzheimer′s diseases through GLP-1 mediated neuroprotective effects [J]. Med Hypotheses，2017，104：4.
[34] Zinman B，Wanner C，Lachin JM，et al. Empagliflozin，cardiovascular outcomes，and mortality in type 2 diabetes [J]. N Engl J Med，2015，373（22）：2117-2128.
[35] Neal B，Perkovic V，Matthews DR. Canagliflozin and cardiovascular and renal events in type 2 diabetes [J]. N Engl J Med，2017，377 （21）：2099. |
|
|
|
